The System That Wasn't in Your Textbook
If you studied biology or physiology before the late 1990s, you probably never heard of the endocannabinoid system. That's not because it didn't exist — it's because it hadn't been discovered yet.
The endocannabinoid system (ECS) is one of the most recently identified major regulatory systems in the human body. Its discovery is a remarkable story of scientific curiosity, political controversy, and the gradual recognition of a biological network that touches nearly every physiological process.
1964: The First Piece of the Puzzle
The story begins not with the endocannabinoid system itself, but with the plant that led to its discovery.
In 1964, Israeli chemist Raphael Mechoulam and his colleague Yechiel Gaoni successfully isolated and synthesized delta-9-tetrahydrocannabinol (THC) — the primary psychoactive compound in cannabis. This was a landmark achievement: for the first time, scientists had a pure, characterized compound they could use to study cannabis's effects in controlled conditions.
Mechoulam's work was conducted at the Weizmann Institute of Science in Rehovot, Israel. The research required obtaining cannabis from the Israeli police — a transaction that, Mechoulam has noted in interviews, involved some creative bureaucratic navigation.
1988: The First Cannabinoid Receptor
For more than two decades after THC's isolation, scientists knew what the compound was but not how it worked. The assumption was that THC, like many lipid-soluble drugs, simply disrupted cell membranes non-specifically.
That assumption was overturned in 1988 when Allyn Howlett and William Devane at the St. Louis University School of Medicine identified the first cannabinoid receptor — now called CB1 — in rat brain tissue. The discovery was significant for two reasons.
First, the existence of a specific receptor meant that THC was not acting non-specifically. It was binding to a dedicated molecular target — which implied that the body had evolved this receptor for a reason.
Second, the distribution of CB1 receptors in the brain was striking. They were densely concentrated in regions associated with memory (hippocampus), motor control (basal ganglia and cerebellum), pain processing (spinal cord and periaqueductal gray), and emotional regulation (amygdala and prefrontal cortex). This distribution mapped almost perfectly onto the known effects of cannabis.
1992: Anandamide and the Endogenous System
The discovery of CB1 receptors raised an obvious question: if the body has receptors for cannabis compounds, does it also produce its own cannabis-like molecules?
The answer came in 1992, when Mechoulam's team — now including William Devane and Lumir Hanus — isolated the first endogenous cannabinoid from pig brain tissue. They named it anandamide, from the Sanskrit word ananda, meaning bliss.
Anandamide was found to bind to CB1 receptors and produce effects similar to THC — though with a much shorter duration due to rapid enzymatic degradation. Its discovery confirmed that the body had its own endocannabinoid system, with endogenous ligands (anandamide and, later, 2-arachidonoylglycerol or 2-AG) and dedicated receptors.
1993: The Second Receptor
A year after anandamide's discovery, a second cannabinoid receptor — CB2 — was identified by Sean Munro and colleagues at the MRC Laboratory of Molecular Biology in Cambridge. Unlike CB1, which is concentrated in the brain and central nervous system, CB2 is expressed primarily in immune tissues: the spleen, tonsils, thymus, and on immune cells.
The discovery of CB2 suggested that the endocannabinoid system had distinct roles in both neurological function (CB1) and immune regulation (CB2) — a scope that made it one of the most broadly distributed regulatory systems in the body.
The Modern Understanding
Over the three decades since these foundational discoveries, the ECS has been found to regulate an extraordinary range of physiological processes:
- Pain perception — through CB1 modulation of pain signaling in the spinal cord and brain
- Appetite and metabolism — CB1 activation in the hypothalamus increases food intake and energy storage
- Immune function — CB2 activation generally produces anti-inflammatory effects
- Memory and learning — CB1 in the hippocampus modulates synaptic plasticity
- Mood and stress response — ECS tone influences anxiety, fear extinction, and HPA axis regulation
- Sleep — endocannabinoid signaling contributes to sleep pressure and sleep stage regulation
- Neuroprotection — endocannabinoids act as retrograde messengers that protect neurons from excitotoxicity
The ECS operates through a unique retrograde signaling mechanism: unlike most neurotransmitters, which are released from the presynaptic neuron and act on the postsynaptic neuron, endocannabinoids are synthesized on demand in the postsynaptic neuron and travel backward across the synapse to modulate the presynaptic neuron's activity. This "on-demand" retrograde signaling allows the ECS to fine-tune neural activity in real time.
Why This History Matters for Hemp Research
The ECS was discovered because scientists were trying to understand how cannabis worked. The irony is that the discovery revealed a system of such fundamental importance that it would have been found eventually regardless of cannabis — it just happened to be cannabis that led us there first.
This history matters for hemp research because it establishes the biological plausibility of hemp extract's effects. When we say that CBD supports endocannabinoid tone by inhibiting anandamide degradation, or that full-spectrum hemp extract modulates CB1 and CB2 receptor activity, these are not marketing claims — they are descriptions of well-characterized molecular mechanisms operating through a system that has been studied for more than three decades.
The research is ongoing. New cannabinoid receptors (GPR55, GPR18, TRPV1) continue to be identified. The interactions between the ECS and other regulatory systems — the immune system, the HPA axis, the circadian clock — are still being mapped. But the foundation is solid, and it was built by some of the most rigorous scientists in modern pharmacology.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Learn how we support your ECS →